Research Advances on Attenuated Listeria monocytogenes as a Vaccine Platform for Cancer Immunotherapy
CHEN Lu1,*, WANG Feng-Ting1,*, SUN Jing1,2,3, CHEN Zhong-Wei1,2,3, WEI Fang-Fang1,2,3, SONG Hou-Hui1,2,3,**, CHENG Chang-Yong1,2,3,**
1 College of Animal Science and Technology·College of Veterinary Medicine, Zhejiang A&F University, Hangzhou 311300, China; 2 Key Laboratory of Applied Technology on Green-Eco-Healthy Animal Husbandry of Zhejiang Province, Hangzhou 311300, China; 3 Zhejiang Provincial Engineering Laboratory for Animal Health Inspection and Internet Technology, Hangzhou 311300, China
Abstract：Listeria monocytogenes is a Gram-positive facultative intracellular bacterial pathogen that can infect humans and animals, causing listeriosis in neonates, pregnant women, elderly persons, and individuals whose immune system is compromised. Live L. monocytogenes is adept at generating strong antigen-specific T-cell responses due to its unique features during host infection, making it an attractive vector for cancer immunotherapy. Increasing studies have shown that the attenuated Listeria is becoming an efficient tool for cancer immunotherapy. Several Listeria-based tumor vaccines undergo being developed, such as the cervical cancer and canine osteosarcoma. Clinical trials have exhibited impressive therapeutic efficacy in these cancer models. This review will summarize the recent studies and progress about Listeria-based cancer immunotherapy, which will help readers understand the current technology and development of tumor immunotherapy vaccines. This review could provide a reference for developing new strategies and technologies for tumor prevention and treatment.
陈璐, 汪枫婷, 孙静, 陈中炜, 卫芳芳, 宋厚辉, 程昌勇. 减毒单增李斯特菌为载体的肿瘤免疫治疗研究进展[J]. 农业生物技术学报, 2021, 29(8): 1622-1629.
CHEN Lu, WANG Feng-Ting, SUN Jing, CHEN Zhong-Wei, WEI Fang-Fang, SONG Hou-Hui, CHENG Chang-Yong. Research Advances on Attenuated Listeria monocytogenes as a Vaccine Platform for Cancer Immunotherapy. 农业生物技术学报, 2021, 29(8): 1622-1629.
[1] Barry M J, Simmons L H.2017. Prevention of prostate cancer morbidity and mortality: Primary prevention and early detection[J]. Medical Clinics of North America, 101(4): 787-806. [2] Basu P, Mehta A, Jain M, et al.2018. A randomized phase 2 study of ADXS11-001 Listeria monocytogenes-Listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer[J]. International Journal of Gynecological Cancer, 28(4): 764-772. [3] Becattini S, Littmann E R, Carter R A, et al.2017. Commensal microbes provide first line defense against Listeria monocytogenes infection[J]. Journal of Experimental Medicine, 214(7): 1973-1989. [4] Bilusic M, Madan R A, Gulley J L.2017. Immunotherapy of prostate cancer: Facts and hopes[J]. Clinical Cancer Research, 23(22): 6764-6770. [5] Bolhassani A, Naderi N, Soleymani S.2017. Prospects and progress of Listeria-based cancer vaccines[J]. Expert Opinion on Biological Therapy, 17(11): 1389-1400. [6] Brahmer J, Johnson M, Awad M, et al.2017. P2. 07-058 first-In-human study of JNJ-64041757, a live attenuated Listeria monocytogenes immunotherapy, for non-small cell lung cancer[J]. Journal of Thoracic Oncology, 12(11): S2151. [7] Chen C, Nguyen B N, Mitchell G, et al.2018. The Listeriolysin O PEST-like sequence Co-opts AP-2-Mediated endocytosis to prevent plasma membrane damage during Listeria Infection[J]. Cell Host & Microbe, 23(6): 786-95 e5. [8] Chen Z, Ozbun L, Chong N, et al.2014. Episomal expression of truncated Listeriolysin O in LmddA-LLO-E7 vaccine enhances antitumor efficacy by preferentially inducing expansions of CD4+FoxP3- and CD8+ T cells[J]. Cancer Immunology Research, 2(9): 911-922. [9] Cheng C, Dong Z, Han X, et al.2017a. Thioredoxin A is essential for motility and contributes to host Infection of Listeria monocytogenes via redox interactions[J]. Frontiers in Cellular and Infection Microbiology, 7: 287. [10] Cheng C, Han X, Xu J, et al.2021. YjbH mediates the oxidative stress response and infection by regulating SpxA1 and the phosphoenolpyruvate-carbohydrate phosphotransferase system (PTS) in Listeria monocytogenes[J]. Gut Microbes, 13(1): 1-19. [11] Cheng C, Jiang L, Ma T, et al.2017b. Carboxyl-terminal residues N478 and V479 required for the cytolytic activity of Listeriolysin O play a critical role in Listeria monocytogenes pathogenicity[J]. Frontiers in Immunology, 8: 1439. [12] Cheng C, Sun J, Yu H, et al.2020. Listeriolysin O pore-forming activity is required for ERK1/2 phosphorylation during Listeria monocytogenes infection[J]. Frontiers in Immunology, 11: 1146. [13] Deng W, Lira V, Hudson T E, et al.2018. Recombinant Listeria promotes tumor rejection by CD8+ T cell-dependent remodeling of the tumor microenvironment[J]. Proceedings of the National Academy of Sciences, 115(32): 8179-8184. [14] Drolia R, Bhunia A K.2019. Crossing the intestinal barrier via Listeria adhesion protein and internalin A[J]. Trends in Microbiology, 27(5): 408-425. [15] Fares E, McCloskey C B, Gutierrez A, et al.2019. Vaccine strain Listeria monocytogenes bacteremia occurring 31 months after immunization[J]. Infection, 47(3): 489-492. [16] Flickinger J C, Rodeck U, Snook A E.2018. Listeria monocytogenes as a vector for cancer immunotherapy: Current understanding and progress[J]. Vaccines (Basel), 6(3): 48. [17] Gaballa A, Guariglia-Oropeza V, Wiedmann M, et al.2019. Cross talk between SigB and PrfA in Listeria monocytogenes facilitates transitions between extra- and intracellular environments[J]. Microbiology and Molecular Biology Reviews, 83(4): e00034-19. [18] Gunn G R, Zubair A, Peters C, et al.2001. Two Listeria monocytogenes vaccine vectors that express different molecular forms of Human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16[J]. The Journal of Immunology, 167(11): 6471-6479. [19] Hanson W G, Benanti E L, Lemmens E E, et al.2019. A potent and effective suicidal Listeria vaccine platform[J]. Infection and Immunity, 87(8): e00144-19. [20] Johansson J, Freitag N E.2019. Regulation of Listeria monocytogenes virulence[J]. Microbiology Spectrum, 7(4): GPP3-0064-2019 [21] Komura K, Sweeney C J, Inamoto T, et al.2018. Current treatment strategies for advanced prostate cancer[J]. International Journal of Urology, 25(3): 220-231. [22] Leitao J H.2020. Listeria monocytogenes as a vector for cancer immunotherapy[J]. Vaccines (Basel), 8(3): 439. [23] Mason N J, Gnanandarajah J S, Engiles J B, et al.2016. Immunotherapy with a HER2-targeting Listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma[J]. Clinical Cancer Research, 22(17): 4380-4390. [24] Matereke L T, Okoh A I.2020. Listeria monocytogenes virulence, antimicrobial resistance and environmental persistence: a review[J]. Pathogens, 9(7): 528. [25] Miles B A, Monk B J, Safran H P.2017. Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy[J]. Gynecologic Oncology Research and Practice, 4: 9. [26] Musser M L, Berger E P, Tripp C D, et al.2021. Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector[J]. Veterinary and Comparative Oncology, 19(1): 92-98. [27] Nguyen B N, Peterson B N, Portnoy D A.2019. Listeriolysin O: A Phagosome-specific cytolysin revisited[J]. Cellular Microbiology, 21(3): e12988. [28] Nguyen B N, Portnoy D A.2020. An inducible Cre-lox system to analyze the role of LLO in Listeria monocytogenes pathogenesis[J]. Toxins (Basel), 12(1): 38. [29] Orbegoso C, Murali K, Banerjee S.2018. The current status of immunotherapy for cervical cancer[J]. Reports of Practical Oncology and Radiotherapy, 23(6): 580-588. [30] Phelps C C, Vadia S, Arnett E, et al.2018. Relative roles of Listeriolysin O, InlA, and InlB in Listeria monocytogenes uptake by host cells[J]. Infection and Immunity, 86(10): e00555-18. [31] Phelps C C, Vadia S, Boyaka P N, et al.2020. A Listeriolysin O subunit vaccine is protective against Listeria monocytogenes[J]. Vaccine, 38(36): 5803-5813. [32] Pillich H, Puri M, Chakraborty T.2017. ActA of Listeria monocytogenes and its manifold activities as an important Listerial virulence factor[J]. Current Topics in Microbiology and Immunology, 399: 113-132. [33] Radoshevich L,Cossart P.2018. Listeria monocytogenes: Towards a complete picture of its physiology and pathogenesis[J]. Nature Reviews. Microbiology, 16(1): 32-46. [34] Roden R B S,Stern P L.2018. Opportunities and challenges for human papillomavirus vaccination in cancer[J]. Nature Reviews Cancer, 18(4): 240-254. [35] Safran H, Leonard K L, Perez K, et al.2018. Tolerability of ADXS11-001 Lm-LLO Listeria-based immunotherapy with mitomycin, fluorouracil, and radiation for anal cancer[J]. International Journal of Radiation Oncology • Biology • Physics, 100(5): 1175-1178. [36] Schafer R, Portnoy D A, Brassell S A, et al.1992. Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine[J]. Journal of Immunology, 149(1): 53-59. [37] Sewell D A, Shahabi V, Gunn G R, 3rd, et al.2004. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7[J]. Cancer Research, 64(24): 8821-8825. [38] Souders N C, Sewell D A, Pan Z K, et al.2007. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer[J]. Cancer Immunity, 7: 2. [39] Sumrall E T, Shen Y, Keller A P, et al.2019. Phage resistance at the cost of virulence: Listeria monocytogenes serovar 4b requires galactosylated teichoic acids for InlB-mediated invasion[J]. PLoS Pathogens, 15(10): e1008032. [40] Sun R, Liu Y.2013. Listeriolysin O as a strong immunogenic molecule for the development of new anti-tumor vaccines[J]. Human Vaccines & Immunotherapeutics, 9(5): 1058-1068. [41] Theisen E, Sauer J D.2016. Listeria monocytogenes and the inflammasome: From cytosolic bacteriolysis to tumor immunotherapy[J]. Current Topics in Microbiology and Immunology, 397: 133-160. [42] Torres-Ibarra L, Cuzick J, Lorincz A T, et al.2019. Comparison of HPV-16 and HPV-18 genotyping and cytological testing as triage testing within human papillomavirus-based screening in Mexico[J]. JAMA Network Open, 2(11): e1915781. [43] Vazquez-Boland J A, Krypotou E, Scortti M.2017. Listeria placental infection[J]. mBio, 8(3): e00949-17. [44] Wang J J, Lei K F, Han F.2018. Tumor microenvironment: recent advances in various cancer treatments[J]. European Review for Medical and Pharmacological Sciences, 22(12): 3855-64. [45] Wendel Naumann R, Leath C A, 3rd.2020. Advances in immunotherapy for cervical cancer[J]. Current Opinion in Oncology, 32(5): 481-487. [46] Wood L M,Paterson Y.2014. Attenuated Listeria monocytogenes: A powerful and versatile vector for the future of tumor immunotherapy[J]. Frontiers in Cellular and Infection Microbiology, 4: 51. [47] Yin Y, Lian K, Zhao D, et al.2017. A promising Listeria-vectored vaccine induces Th1-type immune responses and confers protection against tuberculosis[J]. Frontiers in Cellular and Infection Microbiology, 7: 407. [48] Zhang X, Guan C, Hang Y, et al.2020. An M29 aminopeptidase from Listeria monocytogenes contributes to in vitro bacterial growth but not to intracellular infection[J]. Microorganisms, 8(1): 110.
